Publications
Included here is a list of publications from OCG programs. All published data are available to the research community through the program-specific data matrices.
* denotes publications from the CTD2 initiative that are results of intra-Network collaborations
Study highlights the usage of FDA-approved tyrosine kinase inhibitors for treating leukemia patients with neurotrophic receptor tyrosine kinase mutations.
Integrated analysis of RNA-sequencing, proteomics, and phosphoproteomics data indicate doublecortin like kinase 1 (DCLK1) modulates proteins and pathways associated with cell motility in patient-derived pancreatic ductal adenocarcinoma (PDAC) organoids.
UCSF CTD2 scientists developed a multi-faceted testing framework and demonstrate that analysis of protein networks rather than a single gene identifies synthetic lethal candidates. These candidates are reproducible as they are dependent on genetic and cellular context.
Pages
